Targeted & controlled bone healing
11 Feb 19
Kuros Biosciences signs agreement to supply SeaSpine with bone graft incorporating Kuros’s advanced submicron surface technology

Kuros Biosciences signs agreement to supply SeaSpine with bone graft incorporating Kuros’s advanced submicron surface technology

  • Global partner to market an advanced bone graft supplied by Kuros
  • Agreement demonstrates interest of major orthobiologic companies in Kuros technologies

Schlieren (Zurich), Switzerland, February 11, 2019 – Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a private label Original Equipment Manufacturer (OEM) agreement with SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders.  Under the agreement Kuros will supply the bone graft in various forms and SeaSpine will market the products under the brand name OsteoCurrent in the U.S. and other select markets in Europe, South America and the Middle East providing the necessary regulatory approvals are achieved.  Initial sales in the U.S. are expected prior to the end of H1 2019. Terms of the agreement were not disclosed.

 

Kuros’s proprietary bone graft technology comprises biphasic calcium phosphate with an advanced submicron surface topography that directs bone formation after implantation. With its unique topography, it preferentially directs early wound healing toward the bone-forming pathway, resulting in predictable healing, reliable fusions and an osteoinductive claim in Europe.

 

Joost de Bruijn, Chief Executive Officer of Kuros, said “This is an important agreement, which demonstrates the interest of global orthobiologic companies in Kuros’s technologies and should allow greater penetration of our bone grafting technologies into the US, and other markets.  We look forward to working together with SeaSpine to make OsteoCurrent a success and to improving the bone grafting options for surgeons.”

 

Keith Valentine, Chief Executive Officer of SeaSpine, said “We are excited to partner with Kuros to provide OsteoCurrent to our SeaSpine distributor partners, their surgeons and patients.  We believe OsteoCurrent represents a best of class pure synthetic that will strengthen our product offering.”



Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kurosbio.com

About Kuros

  1. Overview
  2. Executive Committee
  3. Board
  4. Careers

Products

  1. MagnetOs

Pipeline

  1. Pipeline
  2. Spinal fusion
    KUR-113
  3. Fracture repair
    KUR-111
    KUR-113
  4. Surgical Sealants
    Neuroseal (KUR-023)

Technologies

  1. Surface Science Technology
  2. Fibrin-Based
  3. Synthetic Cross-Linking Technology
  4. Immune Modulation

Partnerships

  1. Collaborations
  2. Business Development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & Presentations
  4. Analysts
  5. Calendar
  6. Corporate governance
  7. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Article
11 Feb 19
Kuros Biosciences signs agreement to supply SeaSpine with bone graft incorporating Kuros’s advanced submicron surface technology

Kuros Biosciences signs agreement to supply SeaSpine with bone graft incorporating Kuros’s advanced submicron surface technology

  • Global partner to market an advanced bone graft supplied by Kuros
  • Agreement demonstrates interest of major orthobiologic companies in Kuros technologies

Schlieren (Zurich), Switzerland, February 11, 2019 – Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a private label Original Equipment Manufacturer (OEM) agreement with SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders.  Under the agreement Kuros will supply the bone graft in various forms and SeaSpine will market the products under the brand name OsteoCurrent in the U.S. and other select markets in Europe, South America and the Middle East providing the necessary regulatory approvals are achieved.  Initial sales in the U.S. are expected prior to the end of H1 2019. Terms of the agreement were not disclosed.

 

Kuros’s proprietary bone graft technology comprises biphasic calcium phosphate with an advanced submicron surface topography that directs bone formation after implantation. With its unique topography, it preferentially directs early wound healing toward the bone-forming pathway, resulting in predictable healing, reliable fusions and an osteoinductive claim in Europe.

 

Joost de Bruijn, Chief Executive Officer of Kuros, said “This is an important agreement, which demonstrates the interest of global orthobiologic companies in Kuros’s technologies and should allow greater penetration of our bone grafting technologies into the US, and other markets.  We look forward to working together with SeaSpine to make OsteoCurrent a success and to improving the bone grafting options for surgeons.”

 

Keith Valentine, Chief Executive Officer of SeaSpine, said “We are excited to partner with Kuros to provide OsteoCurrent to our SeaSpine distributor partners, their surgeons and patients.  We believe OsteoCurrent represents a best of class pure synthetic that will strengthen our product offering.”